Clinical trial · Interventional
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening
Multicenter Large-scale Validation Study of the Interest of Broadband Spectroscopy Analysis (Femto/Attosecond by Infrared Laser) on Liquid Biopsies in Breast Cancer Screening
NCT04273542CI-TRIAL-00094901ICRG0101active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to validate the interest of broadband spectroscopy analysis (femto/attosecond by infrared laser) on liquid biopsies in breast cancer screening.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BRCA1 Mutation | — | UNRESOLVED | — |
| BRCA2 Mutation | — | UNRESOLVED | — |
| Breast Cancer Female | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| liquid biopsy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- OTHER
- label
- Control cohort
- description
- In this cohort, women recruited participated to organised breast cancer screening. They must not have an invasive breast cancer. They will have 3 liquid biopsy : the first at inclusion and then at each mammogram every two years (organised breast cancer screening).
- interventionNames
- Other: liquid biopsy
- type
- OTHER
- label
- Patient cohort
- description
- In this cohort, women for who an invasive breast cancer has been diagnose will be included. Only one liquid biopsy will be collected before any treatment.
- interventionNames
- Other: liquid biopsy
- type
- OTHER
- label
- Exploratory cohort
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
\*For all participants :
* Adult woman capable of giving informed consent to research participation
* Affiliation to the French social security system
\>For Control cohort:
* Woman participating in organised screening or benefiting from individual follow-up, eligible as such for a mammogram
\>For Patient cohort:
* woman with invasive breast cancer T0N1, T1N0-1, T2N0-1 (histologically proven) at inclusion and before any cancer treatment
\>For Exploratory cohort:
* woman carrying the BRCA1/2 mutation, followed according to standard recommendations or
* woman carrying the BRCA1/2 mutation suffering from in situ BC discovered on biopsy and histologically confirmed
Exclusion Criteria:
* For all participants :
* Refusal to participate
* Reluctant or unable to comply with study requirements
* Pregnant or breastfeeding woman
* History of breast cancer
* For Patient cohort
\- Patients with Stage III/IV or Bilateral Breast Cancer
* For Control cohort:
* Invasive breast cancer suspected at mammography before liquid biopsy\*
* Mammography classified ACR3 or ACR4
* For Exploratory cohort:
* Concomitant breast cancer
* At inclusion visit, woman for whom an invasive breast cancer will be suspected at mammography will be include in Patient cohort after an histological proof of cancerReferences
Publications (0)
Data not yet available
No reference posted for this study.